When she was born, doctors informed Opal Sandy’s parents that their child would never hear. At the age of 11 months, she had ...

Rapid advances in viral vectors, advanced plasmid DNA and oncology drive new expansion in global markets.Austin, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Gene Therapy Starting Materials Market Size & Growth ...

The gene therapy for neurological diseases market is poised for growth due to rising neurological disorder prevalence, demand ...

The novel treatment, partly developed by CHOP, eliminates the need for regular infusions while preventing the life-threatening bleeds caused by the condition.

Smarter design through targeted delivery and human-relevant testing can save the industry from costly safety failures.

Researchers have achieved the first demonstration in mice of using gene therapy to reverse hallmark symptoms of ...

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and ...

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an announcement. Hansa Biopharma and Genethon have announced successful results from a clinical trial ...

Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...